FDA Approved·United States, United Kingdom, European Union·
Once-Daily Pill for Adults with Untreated CLL or SLL
Jaypirca (pirtobrutinib) — once-daily pill for adults with previously untreated CLL or SLL and no known 17p deletion
This is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not been treated before and have no known 17p deletion. It explains the US prescribing-information section added in October 2026 for Jaypirca (pirtobrutinib), the once-daily oral path through a cancer doctor, and what BRUIN CLL-313 showed against bendamustine plus rituximab.
Hyrnuo (sevabertinib) is a pill for adults with advanced lung cancer and a certain HER2 gene mutation. United States approval is accelerated, including first treatment.
Monthly Shot to Lower Triglycerides and Pancreatitis Risk
Tryngolza (olezarsen) — ApoC-III ASO for severe hypertriglyceridemia (sHTG) and FCS
This is for adults with severe hypertriglyceridemia (fasting TG 500 mg/dL or higher) — and caregivers — who need a labelled way to lower triglycerides and cut the risk of acute pancreatitis, and for…
Breakthrough Brief
Weekly briefs are paused while we strengthen editorial review. To express interest, email info@medcelerator.com.
Special series
Breaking Out: The Weight Class — Shots, Pills, and Organ Labels in 2026
Shots, pills, and organ labels in the 2026 weight class — Wegovy injection, Zepbound, the oral maze, and the process line that authorized is not funded. International by default. Zoom by country. Authorized is not funded.
Once-Daily Pill for FOP Bone Growth in Teens and Adults
Atebrioz (zilurgisertib) — oral ALK2 inhibitor to reduce new heterotopic ossification in FOP (ages 12+)
This is for teens 12 and older and adults with fibrodysplasia ossificans progressiva (FOP) — and caregivers — who need a labelled way to slow new extra bone (heterotopic ossification).
This is for adults with previously treated unresectable, locally advanced, or metastatic bile duct cancer (cholangiocarcinoma) that harbors an FGFR2 gene fusion or other rearrangement — and the…
Once-Weekly Basal Insulin Shot for Adults with Type 2 Diabetes
Onswik (insulin efsitora alfa-gobe) — once-weekly basal insulin for adults with type 2 diabetes
This is for adults with type 2 diabetes — and caregivers helping them — who may be candidates for a once-weekly basal insulin instead of a daily basal shot.
First EU Medicine for Early Brain ALD in Boys Ages 2–12
Nezglyal (leriglitazone) — oral suspension for early cerebral adrenoleukodystrophy (Gd-negative)
This is for boys aged 2 to 12 with early cerebral adrenoleukodystrophy (cALD) — Gd-negative brain lesions on MRI and a Neurological Functional Score of 0 or 1 — and the caregivers helping them.
New Prescription Ointment for Mild-to-Moderate Eczema Ages 2 and Up
Adquey (difamilast) — topical ointment for mild-to-moderate eczema (atopic dermatitis)
This is for people with mild to moderate atopic dermatitis (eczema) — and caregivers of children 2 years and older — who may be candidates for labelled US Adquey ointment.
First FDA-Approved Treatment for MCT8 Peripheral Thyrotoxicosis
Emcitate (tiratricol) — dispersible tablets for peripheral thyrotoxicosis in MCT8 deficiency
This is for people living with MCT8 deficiency (Allan-Herndon-Dudley syndrome) — and the caregivers who help them — who need a realistic route to tiratricol.
This is for adults with superficial basal cell carcinoma — and the caregivers helping them — who may be candidates for labelled US Ameluz red-light PDT with a BF-RhodoLED or RhodoLED XL clinic lamp.
First FDA-Approved Implant Treatment for MacTel Eye Disease
Encelto (revakinagene taroretcel-lwey) — encapsulated cell implant for macular telangiectasia type 2
This is for adults living with idiopathic macular telangiectasia type 2 — and the caregivers who help them — who may be candidates for labelled US Encelto encapsulated cell implants at a…
First FDA-Approved Treatment for Ataxia in Ataxia-Telangiectasia
Aqneursa (levacetylleucine) — oral suspension for ataxia in ataxia-telangiectasia
This is for people living with ataxia-telangiectasia — and the caregivers who help them — who weigh at least 15 kg and may be candidates for labelled US Aqneursa oral suspension for ataxia.